Epithalon vs Testagen

Overview

Epithalon and Testagen are both studied in the peptide research space.

Epithalon: A synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Russian scientist Vladimir Khavinson, claimed to activate telomerase and extend lifespan.

Testagen: The name used for the tetrapeptide Lys-Glu-Asp-Gly (KEDG) in biomedical literature. A human study used a branded peptide complex; equivalence to isolated KEDG and clinical gonadal effects remain unresolved. Published sequence identity, branded-product report.

Evidence Comparison

Testagen evidence scope (September 9, 2026)

The selected Testagen bibliography contains 14 documents: one human branded-product report, seven biological experiments, one materials-science experiment, one computational paper and four reviews. These are documents, not 14 clinical trials or independent cohorts. The selection does not establish comparative clinical benefit, and inherited catalogue labels are not outcome-specific certainty assessments.

The 2011 human report describes 36 men with chronic abacterial prostatitis and androgen deficiency: 20 received oral branded Testagen alongside background treatment and 16 received background treatment alone. Random allocation and blinding are not stated. The AKS-C peptide complex lists four amino acids but is not analytically established as isolated KEDG. Its tables use one undifferentiated pretreatment baseline and significance versus that baseline, without clear between-arm effect estimates. Internal reporting inconsistencies and inadequate safety and attrition reporting further limit interpretation. No human fertility endpoint or reliable purified-KEDG efficacy follows. Primary branded-product report.

Biomedical literature identifies Testagen as Lys-Glu-Asp-Gly (KEDG), a tetrapeptide. The 2011 HeLa work tracks fluorescently labeled peptides and separately examines cell-free binding; it does not establish delivery of an unmodified product to human testes. Five sequence-matched bird papers concern thyroid, thymus or immune/hemostatic outcomes after hypophysectomy, not testosterone, sperm or fertility. Their cohort independence remains unresolved. HeLa and binding report, bird thyroid report, bird immune/hemostatic report, age-specific bird study, bird thyroid morphology, bird thymus report.

The 2020 developer review’s animal reproductive assertions lack a clearly linked original with adequate study detail. Its Testonorm-derived identity statement does not establish equivalence between a tissue preparation, the branded clinical complex and isolated KEDG. The selected reviews do not validate a Testagen-specific Leydig-cell or reproductive mechanism. Developer review, Gene-expression review.

Wheat-histone binding is a cell-free result; transporter modeling does not measure oral uptake or human pharmacokinetics. The 2025 experiment measures copper corrosion, not biological efficacy or safety. Human clinical benefit and long-term safety remain uncertain; the reviewed evidence does not support a treatment or compatibility recommendation. Histone-binding experiment, Transport modeling, Materials-science report.

Aspect	Epithalon	Testagen
Evidence Level	Low	Clinical certainty not formally graded
Human Studies	5	1 branded-product report; isolated KEDG unresolved
Preclinical Studies	15	7 biological + 1 materials experiment; 1 computational paper
Total Sources	28	14 selected documents

Key Differences

Aspect	Epithalon	Testagen
Category	Longevity	Hormonal
Evidence Strength	Low	Clinical certainty not formally graded
Total Sources	28	14 selected documents
Human Studies	5	1 branded-product report; isolated KEDG unresolved

Summary

• Epithalon: Low evidence with 28 total sources (5 human)
• Testagen: 14 selected documents, including one branded-product human report; isolated-KEDG clinical benefit and safety remain uncertain.

---

This comparison is for educational purposes only and is not medical advice. Consult a healthcare professional before making any decisions about peptide use.